These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 310279)
81. A study of antibacterial activity of furbenicillin against beta-lactamase producing gram-negative organisms. Yang YJ; Li JT Chin Med J (Engl); 1984 May; 97(5):345-51. PubMed ID: 6439485 [No Abstract] [Full Text] [Related]
82. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains. Paniagua GL; Monroy E; García O; Vaca S Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741 [TBL] [Abstract][Full Text] [Related]
83. Multiple antibiotic resistance (MAR) index and its reversion in Pseudomonas aeruginosa. Paul S; Bezbaruah RL; Roy MK; Ghosh AC Lett Appl Microbiol; 1997 Mar; 24(3):169-71. PubMed ID: 9080693 [TBL] [Abstract][Full Text] [Related]
84. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Neu HC; Chin NX; Labthavikul P Antimicrob Agents Chemother; 1986 Sep; 30(3):423-8. PubMed ID: 3490827 [TBL] [Abstract][Full Text] [Related]
85. Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase. Easton CJ; Knowles JR Antimicrob Agents Chemother; 1984 Sep; 26(3):358-63. PubMed ID: 6095753 [TBL] [Abstract][Full Text] [Related]
86. A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance. Neu HC; Chin NX Chemioterapia; 1985 Feb; 4(1):63-70. PubMed ID: 3872725 [TBL] [Abstract][Full Text] [Related]
88. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. McLaughlin JC; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; Pfaller MA J Antimicrob Chemother; 1994 Feb; 33(2):223-30. PubMed ID: 8182003 [TBL] [Abstract][Full Text] [Related]
89. The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics. Neu HC; Chin NX Chemioterapia; 1985 Aug; 4(4):271-7. PubMed ID: 3876887 [TBL] [Abstract][Full Text] [Related]
90. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides. Retsema JA; English AR; Girard AE Antimicrob Agents Chemother; 1980 Apr; 17(4):615-22. PubMed ID: 6249192 [TBL] [Abstract][Full Text] [Related]
91. PS-5, a new beta-lactam antibiotic. III. Synergistic effects and inhibitory activity against a beta-lactamase. Okamura K; Sakamoto M; Fukagawa Y; Ishikura T; Lein J J Antibiot (Tokyo); 1979 Apr; 32(4):280-6. PubMed ID: 381269 [TBL] [Abstract][Full Text] [Related]
92. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity. Muñoz Bellido JL; Muñoz Criado S; García García I; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA Antimicrob Agents Chemother; 1997 Dec; 41(12):2612-5. PubMed ID: 9420028 [TBL] [Abstract][Full Text] [Related]
93. Experimental application of the median-effect principle for in vitro quantification of the combined inhibitory activities of clavulanic acid and imipenem against IRT-4 beta-lactamase. Sotto A; Foulongne V; Sirot D; Labia R; Jourdan J Int J Antimicrob Agents; 2002 Jan; 19(1):75-8. PubMed ID: 11814772 [TBL] [Abstract][Full Text] [Related]
94. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. Cheng AF; Ling TK; Lam AW; Fung KS; Wise R J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498 [TBL] [Abstract][Full Text] [Related]
95. Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility. Ferrer-Espada R; Sánchez-Gómez S; Pitts B; Stewart PS; Martínez-de-Tejada G Int J Antimicrob Agents; 2020 Jul; 56(1):105986. PubMed ID: 32335279 [TBL] [Abstract][Full Text] [Related]